
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : NDI-5001
Therapeutic Area : Endocrinology
Study Phase : Preclinical
Sponsor : Sound Bioventures
Deal Size : Undisclosed
Deal Type : Series A Financing
NephroDI Secures Investment to Develop NDI-5001 for Pediatric Kidney Disease
Details : The financing aims to fund the advancement of NephroDI NDI-5001, which is being evaluated in the early-stage clinical trial studies for the treatment of Congenital Nephrogenic Diabetes Insipidus.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
June 20, 2024
Lead Product(s) : NDI-5001
Therapeutic Area : Endocrinology
Highest Development Status : Preclinical
Sponsor : Sound Bioventures
Deal Size : Undisclosed
Deal Type : Series A Financing

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : NDI-5001
Therapeutic Area : Endocrinology
Study Phase : Preclinical
Sponsor : McQuade Center
Deal Size : Undisclosed
Deal Type : Agreement
Details : The agreement aims for the clinical development of NephroDI’s asset, NDI-5001, a novel kidney-targeted small molecule AMPK activator, as a potential therapy for X-linked congenital Nephrogenic Diabetes Insipidus (NDI).
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
June 22, 2023
Lead Product(s) : NDI-5001
Therapeutic Area : Endocrinology
Highest Development Status : Preclinical
Sponsor : McQuade Center
Deal Size : Undisclosed
Deal Type : Agreement

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : NDI-5033
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Xontogeny, LLC
Deal Size : Undisclosed
Deal Type : Financing
Details : NephroDI’s lead product, NDI-5033 is a unique adenosine monophosphate activated kinase (AMPK) activator that can stimulate water reabsorption without causing hypoglycemia, decreasing overall urine output.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
May 12, 2021
Lead Product(s) : NDI-5033
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Xontogeny, LLC
Deal Size : Undisclosed
Deal Type : Financing
